Notícias e Atividades da Kyowa Kirin International

Kyowa Kirin International pertence à Kirin.

Kirin é uma das ...

• Forbes Global 2000 (#1000);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Kirin é uma empresa listada sob o símbolo 2503 (JP).

Kirin tem presença direta em 3 países.

Kirin possui 6 subsidiárias incluindo Coca-Cola Beverages Northeast, Kyowa Chemical Industry e Kyowa Hakko Kirin.

Eles estão dentro:

• Bebidas29%
• Farmacêutica29%
• Outro43%

Fusão, aquisição e financiamento envolvendo Kirin.

• Kyowa Kirin International has announced the acquisition of Orchard Therapeutics  (publicado em 25 de janeiro de 2024).
• Kyowa Kirin International has announced the acquisition of Orchard Therapeutics  (publicado em 6 de outubro de 2023).

Veja o organograma con seus 15 executivos principais

Biografias mais buscadas da Kyowa Kirin International

• Abdul Mullick, President
• Paula Soteropoulos, Director
• Wayne Bowler, Senior Vice President, Business Development & Allian...

Criar um alerta
para seguir os movimentos de executivos da Kyowa Kirin International.

Kirin possui 1.824 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Roche (Suíça).

Popular M&A news in Farmacêutica

• Cyclo Therapeutics adquiriu Rafael Holdings (publicado em 28 de abril de 2025).
• Chimerix and Chimerix have merged  (publicado em 22 de abril de 2025)..
• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Jean-Michel Demeure - Vice President, Finance Global Operations da Sanofi

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Kyowa Kirin International

• Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
• Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day | Orchard Therapeutics
• CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous T-Cell Lymphoma (CTCL)
• Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. | Orchard Therapeutics
• Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome | Orchard Therapeutics
• IR Releases | Investors | Kyowa Kirin Co., Ltd.
• Kyowa Kirin Received Partial Change Approval of LUMICEF® for Palmoplantar Pustulosis in Japan - Kyowa Kirin
• Kyowa Kirin Received Approval for Calcimimetics Agent ORKEDIA® TABLETS 4mg in Japan - Kyowa Kirin
• Kyowa Kirin Received Partial Change Approval of Antineoplastic Mitomycin C Agent in Japan - Kyowa Kirin
• Kyowa Kirin Announces Phase III Study Results of bardoxolone methyl (RTA 402) in Japan and Discontinuation of Development - Kyowa Kirin
• View more press releases Close

Redes sociais sobre Kyowa Kirin International

• Kyowa Kirin International na Wikipedia, Google News e Yahoo Finance
• Kyowa Kirin International na LinkedIn, Twitter e YouTube